Company Overview - Company has submitted a listing application to the Hong Kong Stock Exchange, sponsored by Huatai International [1] - Focuses on developing potential best-in-class targeted therapies in oncology, with core technology centered around the RAS signaling pathway and synthetic lethality mechanisms [1] Product Pipeline - As of the last feasible date, the company has seven self-developed drug candidates, including four in clinical stages, one approved by the National Medical Products Administration (NMPA) and the FDA for IND, and two in preclinical stages [1] - Core product GH21 is a potential best-in-class allosteric SHP2 inhibitor currently in Phase 2 clinical trials, with IND approval for monotherapy in advanced solid tumors obtained in November 2021 [1] - GH21's combination therapies with Gossamer and Osimertinib received IND approvals in June 2024 and November 2023, respectively, and are undergoing Phase 1b/2 and Phase 2 clinical trials in China [1] Additional Drug Candidates - The RAS signaling pathway pipeline includes GH55, a potential best-in-class dual mechanism ERK1/2 inhibitor for treating MAPK pathway-activated solid tumors, currently in Phase 1 clinical trials in China [2] - The synthetic lethality pipeline includes GH56 (MTA synergistic PRMT5 inhibitor), GH2616 (KIF18A inhibitor), and GH31 (MAT2A inhibitor), all of which have received IND approvals and are in various stages of clinical trials in China [2] Market Potential - The global oncology drug market is projected to grow from $262.1 billion in 2024 to $646.1 billion by 2033, while the Chinese market is expected to increase from $37.2 billion to $123.8 billion [2] - Sub-segments such as SHP2 inhibitors and synthetic lethality drugs are anticipated to experience rapid growth in the future [2]

Company Overview - Qinhau Pharmaceutical is a biopharmaceutical company focused on developing potential best-in-class targeted therapies in oncology, with a strong pipeline of innovative candidates centered around the RAS signaling pathway and synthetic lethality mechanisms [2] - The core product GH21 is a potential best-in-class allosteric SHP2 inhibitor currently in Phase 2 clinical trials, having received IND approval for monotherapy in advanced solid tumors from the National Medical Products Administration (NMPA) in November 2021 [2][3] - The company has a pipeline of seven self-developed candidates, including four in clinical stages, one approved by both NMPA and FDA, and two in preclinical stages [3] Clinical Trials and Pipeline - GH21 is undergoing several clinical trials, including a Phase 1b/2 trial in combination with Gossamer and Osimertinib, with IND approvals obtained in June 2024 and November 2023 respectively [3] - GH55, another candidate targeting the RAS signaling pathway, is in a Phase 1 trial for MAPK pathway-activated solid tumors, having received IND approval in September and November 2022 [5] - The company is also developing five candidates leveraging synthetic lethality, including GH56 and GH2616, both in Phase 1 trials, and GH31, which has received IND approval [5][6] Market Potential - The global oncology drug market is projected to grow from $167 billion in 2020 to $262 billion by 2024, with a CAGR of 11.9%, and expected to reach $646 billion by 2033 [10] - The synthetic lethality drug market is anticipated to expand from $2.2 billion in 2020 to $4.2 billion by 2024, with a CAGR of 17.8%, and further increase to $17.6 billion by 2033 [19] - The SHP2 inhibitor market is expected to emerge in 2027, with projections of growth from approximately $329 million in 2029 to about $4.8 billion by 2033, reflecting a CAGR of 95.6% [13] Financial Performance - Qinhau Pharmaceutical reported revenues of approximately 4.69 million RMB for the fiscal year 2024, 3.73 million RMB for the nine months ending September 30, 2024, and 0.981 million RMB for the nine months ending September 30, 2025 [8][9] - The company incurred losses of approximately 1.52 billion RMB for the fiscal year 2024, 965.06 million RMB for the nine months ending September 30, 2024, and 988.87 million RMB for the nine months ending September 30, 2025 [8][9]

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因依賴該等內容而引 致的任何損失承擔任何責任。 Suzhou Genhouse Bio Co., Ltd. 勤浩醫藥（蘇州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代 表 閣下知悉、接納並向勤浩醫藥（蘇州）股份有限公司（「本公司」）、本公司的獨家保薦人、整體協調 人、顧問及包銷團成員表示同意： 於本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前， 不會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務 請僅依據於香港公司註冊處處長註冊的本公司招股章程作出投資決定。該文件的文本將於發售期內向 公眾人士刊發。 * 僅供識 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Suzhou Genhouse Bio Co., Ltd. 勤浩醫藥（蘇州）股份有限公司 (A joint stock company incorporated in the People's Republic of China ...